JP2001064193A - Lavender poultice - Google Patents
Lavender poulticeInfo
- Publication number
- JP2001064193A JP2001064193A JP20213899A JP20213899A JP2001064193A JP 2001064193 A JP2001064193 A JP 2001064193A JP 20213899 A JP20213899 A JP 20213899A JP 20213899 A JP20213899 A JP 20213899A JP 2001064193 A JP2001064193 A JP 2001064193A
- Authority
- JP
- Japan
- Prior art keywords
- poultice
- present
- group
- essential oil
- swelling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】この発明は、ラベンダー精油
の経皮吸収および、その芳香成分（香り）を吸入するこ
とにより人体に影響を及ぼす新規のパップ剤に関するも
のである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a novel cataplasm which percutaneously absorbs lavender essential oil and affects the human body by inhaling its fragrance (aroma).
【０００２】[0002]
【従来の技術】従来の湿布（パップ剤）は薬効成分を経
皮的に吸収させ、鎮痛や消炎作用を起こさせるものがほ
とんどであった。2. Description of the Related Art Most conventional compresses (patch preparations) percutaneously absorb a medicinal ingredient to cause an analgesic or anti-inflammatory effect.
【０００３】[0003]
【発明が解決しようとする課題】経皮吸収だけでなく、
芳香成分（香り）の吸入により嗅覚刺激などを通じて、
ラベンダー精油の有効成分を作用させる湿布（パップ
剤）を提供する。SUMMARY OF THE INVENTION In addition to transdermal absorption,
Through inhalation of aroma components (scents) through olfactory stimulation,
Provided is a poultice (poultice) on which the active ingredient of lavender essential oil acts.
【０００４】[0004]
【課題を解決するための手段】薬剤を含まない湿布（パ
ップ剤）にラベンダー精油を混入し、患部に貼用する。
本発明は以上の構成になっている。Means for Solving the Problems Lavender essential oil is mixed in a compress containing no medicine (a poultice) and applied to the affected area.
The present invention has the above configuration.
【０００５】[0005]
【発明の実施の形態】本発明を詳細に説明する。湿布
（パップ）剤に、真性ラベンダー精油または、その代用
品であるラバンジン精油を適量混入し、患部に貼用す
る。患部とは例えば骨折・脱臼・捻挫・打撲・挫傷など
の急性期またはスポーツや労働後の疲労した筋肉や関節
などを指す。ラベンダーの成分は主成分の酢酸リナリル
とリナロールをはじめとして、１００種類以上の化学成
分によって出来ている。これら成分の効能により鎮痛作
用、抗炎症作用、消毒作用、癒症作用は経皮的吸収によ
りあらわれる。また、本発明は経皮的に精油の有効成分
が吸収され効果をあらわすだけでなく、揮発した精油に
よる吸入効果を最大の特徴とする。ラベンダーに含まれ
る酢酸リナリル、リナロールは吸入をとうして吸収さ
れ、鎮静作用を発揮することは数多くの文献で指摘され
ており、本発明においても吸入による鎮静効果が期待で
きる。DETAILED DESCRIPTION OF THE INVENTION The present invention will be described in detail. An appropriate amount of essential lavender essential oil or its substitute, lavandin essential oil, is mixed into a poultice (pap) agent and applied to the affected area. The affected part refers to, for example, muscles and joints that are in an acute stage such as a fracture, dislocation, sprain, bruise, bruise, or fatigue after sports or work. Lavender is made up of over 100 chemical components, including the main components linalyl acetate and linalool. The analgesic, anti-inflammatory, disinfecting and healing effects are manifested by percutaneous absorption due to the efficacy of these components. In addition, the present invention is characterized not only by the percutaneous absorption of the active ingredient of the essential oil, but also by the inhalation effect of the volatile essential oil. It has been pointed out in many literatures that linalyl acetate and linalool contained in lavender are absorbed through inhalation and exert a sedative effect, and a sedative effect by inhalation can also be expected in the present invention.
【０００６】[0006]
【表１】本発明使用群における疼痛、腫脹の推移Table 1 Changes in pain and swelling in the group of the present invention
【表２】本発明未使用群における疼痛、腫脹の推移（冷
却シートのみ）[Table 2] Changes in pain and swelling in the group not using the present invention (cooling sheet only)
【図１】本発明未使用群における疼痛の推移図（冷却シ
ートのみ）[FIG. 1] Transition of pain in the group not using the present invention (only cooling sheet)
【図２】本発明使用群における疼痛の推移図FIG. 2 is a transition diagram of pain in the group of the present invention.
【図３】本発明未使用群における腫脹の推移図（冷却シ
ートのみ）FIG. 3 is a transition diagram of swelling in an unused group of the present invention (only cooling sheet)
【図４】本発明使用群における腫脹の推移図FIG. 4 is a transition diagram of swelling in the group using the present invention.
【図１、図２、図３、図４の解説】図１は（疼痛）本発
明未使用群 図２は（疼痛）本発明使用群図３は（腫
脹）本発明未使用群 図４は（腫脹）本発明使用群とし
て面グラフで表示した。５日間の疼痛や腫脹の残存度は
面の合計面積に現れるようにした。各図の横軸に症例数
を、縦軸に疼痛、腫脹の残存度を記載した。まず疼痛の
比較では、初診時の１０（１００％）に対し、再来院時
（回復の経過を色分けした面にて表示）図１．図２．と
もに軽減されているが、本発明使用群（図２）では、本
発明未使用群（図１）に比べ、特に４−５日後におい
て、より疼痛の軽減度が大きいことが解る。次に腫脹の
比較だが、（腫脹）本発明使用群（図４）は疼痛の比較
よりもさらに（腫脹）本発明未使用群（図３）との面積
差は大きくなっていることが読みとれる。この図の比較
から本発明使用群は腫脹の消失までの時間は著しく短縮
されていることがわかる。本発明使用群の場合、これら
の図からは不十分ではあるが、治癒までの期間もかなり
短縮されていることが解った。また、本発明使用群の全
症例で皮膚のかぶれなどはなかった。その他では、多数
の患者から、その香りについて「良い香りである」「落
ち着く」との反応があった。ラベンダー油の香りはその
鎮静作用から、新鮮外傷時の緊張状態にある患者に対し
作用したようで好評であった。FIG. 1, FIG. 2, FIG. 3, FIG. 4 FIG. 1 is a (pain) non-use group of the present invention FIG. 2 is a (pain) use group of the present invention FIG. 3 is a (swelling) non-use group of the present invention FIG. (Swelling) Areas of use according to the present invention are shown in an area graph. The persistence of pain and swelling for 5 days was shown in the total area of the surface. In each figure, the horizontal axis represents the number of cases, and the vertical axis represents the degree of residual pain and swelling. First, in the comparison of pain, 10 (100%) at the first consultation, at the time of return to the hospital (the progress of recovery is indicated by a color-coded surface). FIG. Both are reduced, but it can be seen that the degree of pain reduction is greater in the group using the present invention (FIG. 2) than in the group not using the present invention (FIG. 1), especially after 4-5 days. Next, when comparing the swelling, it can be seen that the area difference between the (swelling) group using the present invention (FIG. 4) and the (swelling) group not using the present invention (FIG. 3) is larger than that of the pain comparison. . From the comparison of the figures, it can be seen that the time required for the swelling to disappear in the group of the present invention is significantly reduced. In the case of the group using the present invention, it is understood from these figures that the period until healing is considerably shortened, although it is insufficient. In addition, there was no rash on the skin in all cases in the group of the present invention. In other cases, many patients responded that the scent was "good scent" and "calm down". Due to its sedative effect, the scent of lavender oil seemed to have worked well on patients who were nervous during fresh trauma.
【０００７】[0007]
【発明の効果】本発明を利用することにより、患部の腫
脹、疼痛が著明に改善する。また芳香の吸入による鎮静
効果により、受傷時のショックからもすみやかに、回復
することができる。According to the present invention, swelling and pain of the affected area are remarkably improved. In addition, the sedative effect of inhalation of the fragrance can promptly recover from the shock at the time of injury.
【表１】 [Table 1]
【表２】 [Table 2]
─────────────────────────────────────────────────────
────────────────────────────────────────────────── ───
【手続補正書】[Procedure amendment]
【提出日】平成１１年８月３１日（１９９９．８．３
１）[Submission date] August 31, 1999 (1999.8.3)
1)
【手続補正２】[Procedure amendment 2]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】図面の簡単な説明[Correction target item name] Brief description of drawings
【補正方法】変更[Correction method] Change
【補正内容】[Correction contents]
【図面の簡単な説明】[Brief description of the drawings]
【図１】 本発明未使用群における疼痛の
推移図FIG. 1 is a transition diagram of pain in a group not using the present invention.
【図２】 本発明使用群における疼痛の推
移図FIG. 2 is a transition diagram of pain in the present invention use group.
【図３】 本発明未使用群における腫脹の
推移図FIG. 3 is a transition diagram of swelling in an unused group of the present invention.
【図４】 本発明使用群における腫脹の推
移図FIG. 4 is a transition diagram of swelling in the group using the present invention.
Claims (1)
まない湿布（パップ剤）1. An agent-free poultice prepared by mixing lavender essential oil into a poultice (poultice)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20213899A JP2001064193A (en) | 1999-06-12 | 1999-06-12 | Lavender poultice |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20213899A JP2001064193A (en) | 1999-06-12 | 1999-06-12 | Lavender poultice |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2001064193A true JP2001064193A (en) | 2001-03-13 |
Family
ID=16452599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP20213899A Pending JP2001064193A (en) | 1999-06-12 | 1999-06-12 | Lavender poultice |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2001064193A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1374883A1 (en) * | 2002-06-21 | 2004-01-02 | Roland. Dr. Lingg | Nasal spray containing a plant extract for the treatment of diseases such as herpes zoster, hematoma, mastitis and cardiovasculatory weakness |
| FR2846235A1 (en) * | 2002-10-29 | 2004-04-30 | Oreal | COSMETIC PROCESS FOR SMOOTHING EXPRESSION WRINKLES BY TOPICAL APPLICATION OF PERFUME COMPOSITION |
| GB2412585A (en) * | 2004-04-01 | 2005-10-05 | David Andrew Jackson | Muscle treatment using a combination of essential oils |
| CN104208333A (en) * | 2014-09-03 | 2014-12-17 | 陈英武 | Bone-killing pain-relieving composition and preparation method of medicament |
| CN104524483A (en) * | 2015-02-02 | 2015-04-22 | 范晓华 | Tincture for promoting bone injury healing and preparation method thereof |
| CN104623447A (en) * | 2015-03-04 | 2015-05-20 | 张晓利 | Traditional Chinese medicine for treating femoral neck fracture and preparation method thereof |
| JP2017522269A (en) * | 2014-05-20 | 2017-08-10 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Transdermal therapeutic system containing lavender oil |
-
1999
- 1999-06-12 JP JP20213899A patent/JP2001064193A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1374883A1 (en) * | 2002-06-21 | 2004-01-02 | Roland. Dr. Lingg | Nasal spray containing a plant extract for the treatment of diseases such as herpes zoster, hematoma, mastitis and cardiovasculatory weakness |
| FR2846235A1 (en) * | 2002-10-29 | 2004-04-30 | Oreal | COSMETIC PROCESS FOR SMOOTHING EXPRESSION WRINKLES BY TOPICAL APPLICATION OF PERFUME COMPOSITION |
| EP1415644A1 (en) * | 2002-10-29 | 2004-05-06 | L'oreal | Cosmetic process for smoothing out expression wrinkles by topical application of a perfume composition |
| GB2412585A (en) * | 2004-04-01 | 2005-10-05 | David Andrew Jackson | Muscle treatment using a combination of essential oils |
| GB2412585B (en) * | 2004-04-01 | 2007-11-14 | David Andrew Jackson | Muscle treatment |
| JP2017522269A (en) * | 2014-05-20 | 2017-08-10 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Transdermal therapeutic system containing lavender oil |
| CN104208333A (en) * | 2014-09-03 | 2014-12-17 | 陈英武 | Bone-killing pain-relieving composition and preparation method of medicament |
| CN104524483A (en) * | 2015-02-02 | 2015-04-22 | 范晓华 | Tincture for promoting bone injury healing and preparation method thereof |
| CN104623447A (en) * | 2015-03-04 | 2015-05-20 | 张晓利 | Traditional Chinese medicine for treating femoral neck fracture and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5976547A (en) | Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery | |
| Hill et al. | Closed treatment of displaced middle-third fractures of the clavicle gives poor results | |
| Christian et al. | Reconstruction of large diaphyseal defects, without free fibular transfer, in Grade-IIIB tibial fractures. | |
| Vestergaard et al. | Fracture rates and risk factors for fractures in patients with spinal cord injury | |
| Onuminya | The role of the traditional bonesetter in primary fracture care in Nigeria | |
| DE3927113C2 (en) | Agent for the treatment of severe pain conditions and process for their preparation | |
| KR20010014683A (en) | Blood Circulation-Promoting Powdery Material, Blood Circulation-Promoting Attachment Sheet and Blood Circulation-Promoting Attachment Sheet Set | |
| JP2001097878A (en) | Compositions for treating rheumatism and method for producing the same | |
| KR20070088264A (en) | Anorectic agent and air regulator for diet | |
| EP1196183B1 (en) | Oregano-based therapeutic composition | |
| US20020107188A1 (en) | Method of treating inflammation in the joints of a body | |
| JP2001064193A (en) | Lavender poultice | |
| Rosenberg et al. | Shoulder impairment following treatment of diaphysial fractures of humerus by functional brace | |
| US8821948B2 (en) | Therapeutic, bio-affecting and body treating composition | |
| DOWLING et al. | Treatment of fractures in burn patients | |
| CN112546183A (en) | Health-care plaster containing Chinese mugwort, navel and red bean | |
| CN1520846A (en) | Quick-effective aerosol with plant aroma and its preparation | |
| CN100486640C (en) | Externally applied medicine for treating neck and waist arthrosis | |
| CN108465036A (en) | A kind of remedy,toothache and middle powder stick item | |
| CN1231920A (en) | Formulation of medicine for treating scrofula, and its preparing process | |
| KR20050116674A (en) | Human body administration gold thread and disposable gold thread syringe for curing disease using gold thread | |
| WO1986002270A1 (en) | Cough-relieving compositions | |
| CN1066334C (en) | Medicines for treating bone tuberculosis, osteomyelities medullitis and other swelling pain | |
| Bramlage et al. | Evaluation of stainless steel nerve caps for palmar digital neurectomy | |
| GB2416664A (en) | Natural foot therapy pad |